glp 1 during perimenopause GLP-1 Microdosing for Perimenopause: Benefits & Risks Let's talk about GLP-1 medications

Mitnala, S

I.BaryckiJ

I cant say enough good things about River Oaks Drip Spa

Yes but with conditions

Analysis of relative gene expression data using real-time quantitative PCR and the 2 CT method

Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied